Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LLY
stocks logo

LLY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.71B
+30.84%
7.156
+34.5%
17.31B
+35.97%
7.541
+125.79%
18.52B
+19.01%
7.944
+25.89%
Estimates Revision
The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 3.24% over the past three months. During the same period, the stock price has changed by 39.50%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4%
In Past 3 Month
Stock Price
Go Up
up Image
+39.50%
In Past 3 Month
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1035 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1035 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1014.490
sliders
Low
800.00
Averages
1035
High
1300
Current: 1014.490
sliders
Low
800.00
Averages
1035
High
1300
Guggenheim
Buy
maintain
2025-12-03
New
Reason
Guggenheim
Price Target
2025-12-03
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Eli Lilly (LLY) to $1,163 from $1,036 and keeps a Buy rating on the shares after updating the firm's Lilly and Novo Nordisk (NVO) models to reflect prescription trends and GLP-1 pricing updates and announcements. While noting that Lilly has "delivered another impressive year of stock performance in 2025," the firm "simply cannot argue with the company's superior overall execution capitalizing fully on the Pharma mega cycle of our lifetime," the analyst tells investors.
Morgan Stanley
NULL
to
Overweight
maintain
2025-11-24
Reason
Morgan Stanley
Price Target
2025-11-24
maintain
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on Eli Lilly to $1,290 from $1,171 and keeps an Overweight rating on the shares. The firm refreshed its model assumptions to incorporate recent developments in the GLP-1 space as well as insights from a proprietary primary care physician survey, the analyst tells investors.
Bernstein
Outperform
maintain
2025-11-24
Reason
Bernstein
Price Target
2025-11-24
maintain
Outperform
Reason
Bernstein raised the firm's price target on Eli Lilly to $1,300 from $1,100 and keeps an Outperform rating on the shares. The firm cites a catalyst path and earnings upside over the next 24 months-plus driven by Orforglipron launch, Trump GLP1 deal and ex-U.S. expansion.
JPMorgan
Chris Schott
Overweight
maintain
2025-11-18
Reason
JPMorgan
Chris Schott
Price Target
2025-11-18
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Eli Lilly to $1,150 from $1,050 and keeps an Overweight rating on the shares after meetings with management. The firm says the meetings reinforced its positive view on the story. JPMorgan increasingly sees Lilly's agreement with the Trump Administration expanding access to obesity medicines as a net positive. Incremental volumes will more than offset the price cuts, the analyst tells investors in a research note. This, coupled with ongoing U.S. market share gains and an underpenetrated international obesity opportunity, position Lilly for significant growth in 2026 and beyond, contends JPMorgan.
Scotiabank
initiated
$1,165
2025-11-12
Reason
Scotiabank
Price Target
$1,165
2025-11-12
initiated
Reason
Scotiabank initiated coverage of Eli Lilly with an Outperform rating and $1,165 price target.
Citi
Buy
maintain
2025-11-12
Reason
Citi
Price Target
2025-11-12
maintain
Buy
Reason
Citi raised the firm's price target on Eli Lilly to $1,500 from $1,250 and keeps a Buy rating on the shares. The firm sees Lilly's "domination" of the weight loss category accelerating following last week's agreement with the U.S. government for Medicare and Medicaid access. Citi sees an over $40B peak sales opportunity for Lilly's weight loss treatments and increased 2026 estimates.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 33.21, compared to its 5-year average forward P/E of 40.17. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
40.17
Current PE
33.21
Overvalued PE
51.98
Undervalued PE
28.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
30.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
37.74
Undervalued EV/EBITDA
22.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.98
Current PS
0.00
Overvalued PS
13.88
Undervalued PS
8.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LLY News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-12-03 (ET)
2025-12-03
16:20:00
Major US Indices Close Higher as Markets Price in Fed Rate Cut This Month
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedFDA Broadens Approval for Lilly's Cancer Treatment Jaypirca

  • FDA Approval Expansion: Eli Lilly's cancer medication Jaypirca has received expanded FDA approval for treating adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously been treated with a BTK inhibitor.

  • Transition to Full Approval: The FDA's decision allows Jaypirca to be used earlier in treatment and converts its December 2023 accelerated approval for later-stage CLL/SLL into a full, traditional approval.

  • Initial Approval and Revenue: Jaypirca was initially approved in January 2023 for mantle cell lymphoma and has generated significant revenue, recording $337 million in 2024 and $358 million for the first nine months of 2025.

  • Market Performance: Eli Lilly's stock closed at $1,033.56, reflecting a 1.20% decrease in trading on Wednesday.

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedFDA Gives Complete Approval to Eli Lilly's Jaypirca for CLL/SLL Treatment

  • FDA Approval: Eli Lilly's Jaypirca (pirtobrutinib) has been approved by the FDA for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent BTK inhibitor.

  • Expanded Access: The approval allows for broader access to Jaypirca, now including patients earlier in their treatment journey, and converts its previous accelerated approval into a traditional approval based on strong clinical data.

  • Unique Mechanism: Jaypirca is the first FDA-approved non-covalent BTK inhibitor, utilizing a novel reversible binding mechanism to target the BTK pathway in patients previously treated with covalent BTK inhibitors.

  • Stock Performance: Following the announcement, Eli Lilly's stock experienced a decline, closing at $1,033.56, down 1.20%, with further losses in overnight trading.

[object Object]
Preview
4.5
12:05 PMYahoo Finance
Dow Jones Futures Climb Following Small Cap Rally; Eli Lilly Under Review; 5 Stocks in Buying Range
  • Small Caps Performance: Small cap stocks are approaching all-time highs while major indexes have paused in their movements.
  • Eli Lilly's Position: Eli Lilly is currently at a significant price level that investors are watching closely.
  • Robinhood's Activity: Robinhood has emerged as a leader in new stock purchases among investors.
  • Ulta Beauty Earnings: Ulta Beauty has reported its earnings, leading the market in this reporting period.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eli Lilly and Co (LLY) stock price today?

The current price of LLY is 1014.49 USD — it has decreased -1.85 % in the last trading day.

arrow icon

What is Eli Lilly and Co (LLY)'s business?

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).

arrow icon

What is the price predicton of LLY Stock?

Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1035 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eli Lilly and Co (LLY)'s revenue for the last quarter?

Eli Lilly and Co revenue for the last quarter amounts to 17.60B USD, increased 53.87 % YoY.

arrow icon

What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?

Eli Lilly and Co. EPS for the last quarter amounts to 6.21 USD, increased 480.37 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 3.24% over the past three months. During the same period, the stock price has changed by 39.50%.
arrow icon

How many employees does Eli Lilly and Co (LLY). have?

Eli Lilly and Co (LLY) has 47000 emplpoyees as of December 05 2025.

arrow icon

What is Eli Lilly and Co (LLY) market cap?

Today LLY has the market capitalization of 959.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free